Drinabant - Opiant Pharmaceuticals
Alternative Names: AVE 1625; INDV-5004; OPNT-004Latest Information Update: 05 Nov 2023
At a glance
- Originator sanofi-aventis
- Developer Opiant Pharmaceuticals; sanofi-aventis
- Class Antidementias; Antihyperglycaemics; Antiparkinsonians; Antipsychotics; Halogenated hydrocarbons; Obesity therapies; Small molecules; Sulfonamides
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Substance-related disorders
- Discontinued Alzheimer's disease; Obesity; Parkinson's disease; Schizophrenia; Type 2 diabetes mellitus
Most Recent Events
- 02 Mar 2023 Opiant Pharmaceuticals has been acquired by Indivior
- 27 Dec 2022 Preclinical development is ongoing in USA (Parenteral) (Opiant Pharmaceuticals pipeline, December 2022)
- 22 Aug 2022 Opiant Pharmaceuticals receives patent allowance for drinabant for the treatment of cannabinoid hyperemesis syndrome in US